We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Momenta, Sandoz Again Try To Nix Amphastar's Antitrust Suit

Law360, Fort Wayne (April 20, 2017, 5:54 PM EDT) -- Momenta and Sandoz on Thursday asked a Massachusetts federal judge to toss a revived antitrust suit by Amphastar claiming they stifled competition for generic anticoagulant enoxaparin, saying there have been no barriers to selling the drug.

Amphastar Pharmaceuticals Inc. alleges that Momenta Pharmaceuticals Inc. tricked the U.S. Pharmacopeial Convention into adopting a method to test enoxaparin without disclosing that it held a patent that covered the test, but Momenta and Sandoz Inc. said in a motion to dismiss that the method was not mandatory.

The U.S....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.